Skip to content
The COVID Project
  1. Library
  2. Other federal health agencies
  3. AGY-FED-HEALTH-OTHER-020

Ex. AGY-FED-HEALTH-OTHER-020 Order Primary source read

DEA-DC-030 (DEA087), letter extending the off-site take-home delivery flexibility to buprenorphine dispensed by opioid treatment programs

Off site OTP delivery buprenorphine

Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA · United States (federal); Drug Enforcement Administration, Diversion Control Division (Federal)

Open exhibit (PDF, 181 KB)Source (opens in a new tab)
The COVID Project

The record

Jurisdiction
United States (federal); Drug Enforcement Administration, Diversion Control Division
Level
Federal
Authority
21 U.S.C. 822(e); 21 C.F.R. 1301.12; 21 C.F.R. 1307.03
Issued
2020-04-21 Apr. 21, 2020
Effective
2020-04-21
End
During the public health emergency or until withdrawn or modified by DEA (read as 2021-09-30)
In force
Apr. 21, 2020 to Sept. 30, 2021
Quarters
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
Limitation types
Health care ordersOther
Addressees
  • DEA-registered narcotic treatment programs
Functions reached
  • CL clinical dispensing
  • TR transport
  • CB patients
Collection
Other federal health agencies AGY-FED-HEALTH-OTHER

Operative words

DEA is now extending the same flexibility to OTPs in how they deliver take-home doses of buprenorphine. As with methadone, DEA is temporarily allowing OTPs to regularly use the same off-site location to deliver take-home buprenorphine doses to their patients without separately registering that location with DEA, subject to the same conditions as expressed in the April 7 methadone guidance document.

Enforcement

Registration requirements under 21 U.S.C. 822(e) and 842

A record of The COVID Project. The instrument's text is the source's; the summary fields are The COVID Project's reading of it. Not legal advice.